Undisclosed KCNQ1 modulator
/ Beijing Sungen Biomedical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 05, 2026
Development of a First-in-Class KCNQ1-Targeting Monoclonal Antibody for Precision Therapy of Long QT Syndrome
(AHA 2026)
- No abstract available
Cardiovascular • KCNQ1OT1
1 to 1
Of
1
Go to page
1